August 2026– date –
-
AI’s Performance Breakthrough: Advanced Packaging, Power, and Interconnects Take Center Stage at SEMI Europe 2026
SEMI Europe Europe Overview SEMI Europe's 2026 Advanced Packaging Conference (APC) will spotlight 'Power and Interconnects Innovations Enabling AI System Performance,' emphasizing advanced packaging (AP) and test as crucial for scaling n... -
Cell Membrane-Coated Nanoparticles: New Strategy for Diabetic Wound Healing, Macrophage and Mesenchymal Stem Cell Membranes Show Significant Anti-Inflammatory, Angiogenic, and Tissue Repair Effects
PMC (PubMed Central) International Overview Nanoparticles are a promising platform for drug delivery, and specifically for diabetic wound healing, cell membrane-coated nanoparticles have emerged as an innovative strategy due to their inh... -
Enzene Unveils New “NeX” Partnership Model to Expand Global Biologics Manufacturing: Cutting Capital Costs and Accelerating Facility Deployment
PharmaSource India Overview Enzene Biosciences Limited has launched "NeX," an end-to-end partnership model designed to help governments, institutions, and biopharmaceutical companies establish local biologics manufacturing capabilities. ... -
AsymBio Secures $184 Million in Funding to Expand Biologics CDMO Operations, Boosting ADC and Bispecific Antibody Manufacturing Capacity
Pharma Manufacturing China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (RMB 1.24 billion) in new funding to significantly expand its biologics development and manufacturing operations... -
Resilience and Eli Lilly Invest $750 Million to Boost U.S. Medicine Supply, Expanding Biologics, Cell Therapy, and Aseptic Manufacturing
Resilience USA Overview Resilience has announced a $750 million investment in new pharmaceutical manufacturing in Ohio, expanding its strategic partnership with Eli Lilly to bolster the U.S. medicine supply. Resilience operates as a comp... -
FDA Grants Fast Track and Priority Review to Multiple Cancer Drugs in July 2026: Insilico Medicine’s ISM6331 Receives Designation for Mesothelioma
Pharmacy Times USA Overview In July 2026, the FDA granted Fast Track Designation and Priority Review to several oncology therapeutics, targeting colorectal cancer, anal cancer, malignant pleural mesothelioma, and large B-cell lymphoma. N... -
Large Language Models Accelerate Small-Molecule Drug Discovery: Structure-Guided AI System “MolecularCanvas” Streamlines Generation and Evaluation
arXiv International Overview An interactive system named "MolecularCanvas," powered by Large Language Models (LLMs), has been developed to accelerate iterative molecular optimization in small-molecule drug discovery. This system guides t... -
Focused Ultrasound Dramatically Enhances Brain Tumor Drug Delivery: Mid-Sized Molecules Most Effective, Ushering in a New Era of Non-Invasive Therapy
Neuroscience News USA Overview New research shows focused ultrasound (FUS) combined with microbubbles is highly effective for targeted drug delivery to primary brain tumors (gliomas). This non-invasive technique temporarily and reversibl... -
Insilico Medicine Nominates ISM9077, Potential First-in-Class AI-Designed Target Y Inhibitor, as Preclinical Candidate for Ocular, Inflammatory, and Aging Disorders
Barchart.com (Insilico Medicine Press Release) Hong Kong Overview Insilico Medicine nominated ISM9077, a potential first-in-class Target Y inhibitor, as a preclinical candidate (PCC) for ocular diseases, inflammatory disorders, and aging... -
Oral GLP-1 Market Soars: Eli Lilly’s Foundayo and Novo Nordisk’s Oral Wegovy Reach New Prescription Highs
Fierce Pharma USA Overview Weekly prescriptions for Eli Lilly's oral GLP-1 agonist Foundayo and Novo Nordisk's oral Wegovy have reached new highs, demonstrating the significant impact of oral GLP-1 drugs on the obesity treatment landscap...
